REFERENCES
[1] Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis.
Lancet. 2021; 397(10290): 2195-2211.
[2] Cystic Fibrosis Mutation Database.
http://www.genet.sickkids.on.ca/cftr/StatisticsPage.html. Accessed
January 8, 2022.
[3] Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and
clinical aspects. Animal Model Exp Med. 2021; 4(3): 220-232.
[4] Shen Y, Liu J, Zhong L, et al. Clinical Phenotypes and Genotypic
Spectrum of Cystic Fibrosis in Chinese Children. J Pediatr. 2016;171:
269-76.e1.
[5] Burgel PR, Munck A, Durieu I, et al. Real-Life Safety and
Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
Am J Respir Crit Care Med. 2020;201(2): 188-197.
[6] Shen Y, Tang X, Liu J, Li H, Zhao S. Pseudo-Bartter syndrome in
Chinese children with cystic fibrosis: Clinical features and genotypic
findings. Pediatr Pulmonol. 2020;55(11): 3021-3029.
[7] Tian X, Liu Y, Yang J, et al. p.G970D is the most frequent CFTR
mutation in Chinese patients with cystic fibrosis. Hum Genome Var.
2016;3: 15063.
[8] Bergougnoux A, Délétang K, Pommier A, et al. Functional
characterization and phenotypic spectrum of three recurrent
disease-causing deep intronic variants of the CFTR gene. J Cyst Fibros.
2019;18(4): 468-475.
[9] Scotet V, L', Hostis C, Férec C. The Changing Epidemiology
of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene
Discovery. Genes (Basel). 2020;11(6).
[10] Bell SC, Mall MA, Gutierrez H, et al. The future of cystic
fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):
65-124.
[11] Parkins MD, Somayaji R, Waters VJ. Epidemiology, Biology, and
Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.
Clin Microbiol Rev. 2018;31(4).
Figure 1. Timeline of the course of disease for an 11-year-old Chinese
boy with CF